title: Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma.
abstract: The acquisition of resistance to current mitogen activated protein kinase (MAPK) inhibitors in B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutant melanoma is almost inevitable. Our recent findings identify therapy-induced mitochondrial biogenesis (MitoBiogenesis) and aberrant tumor bioenergetics as therapeutic escape mechanisms and offer a rational combinatorial strategy to further improve the efficacy of MAPK inhibitors.
authors.affiliation: Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute , Philadelphia, PA, USA.
authors.forename: Lawrence W
authors.initials: LW
authors.lastname: Wu
authors.affiliation: Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute , Philadelphia, PA, USA.
authors.forename: Gao
authors.initials: G
authors.lastname: Zhang
authors.affiliation: Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute , Philadelphia, PA, USA.
authors.forename: Meenhard
authors.initials: M
authors.lastname: Herlyn
keywords: BRAF-mutant melanoma; mitochondrial biogenesis; targeted therapies